Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 339 publications
Intratumoral dose heterogeneity promotes adaptive anti-tumor immunity and predicts clinical response to radiopharmaceutical therapy.
Journal: bioRxiv : the preprint server for biology
Published: August 01, 2026
Re: [177Lu]-PSMA-617-PSMA-617 in Oligometastatic Hormone Sensitive Prostate Cancer (BULLSEYE): An Open-label, Randomised, Phase 2 Study.
Journal: European urology
Published: June 12, 2026
NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: May 14, 2026
Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis.
Journal: European urology
Published: May 11, 2026
Dosimetric analysis of post-radiotherapy sexual dysfunction in patients receiving definitive stereotactic body radiotherapy (SBRT) for prostate cancer: a secondary analysis of MIRAGE.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: April 16, 2026
A Multidisciplinary Approach to Prevention and Treatment of Late Genitourinary Adverse Events After Radiotherapy for Prostate Cancer.
Journal: European urology
Published: April 13, 2026
Reply to: Comments on the LUNAR Trial in Oligorecurrent Hormone-Sensitive Prostate Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 18, 2026
Defining Intraprostatic Gross Tumor Volume and Micro-boosting through Consensus: A Contour-Based Modified Delphi Consensus.
Journal: International journal of radiation oncology, biology, physics
Published: March 16, 2026
Stereotactic radiotherapy for rib metastases from prostate cancer: A multicenter real-world analysis of local control, pain response, and treatment tolerance (RIBRISK).
Journal: Therapeutic advances in medical oncology
Published: March 14, 2026
Interference of clonal hematopoiesis in cfDNA liquid biopsy testing and identification of actionable alterations in large diverse cohort of US veterans.
Journal: The oncologist
Published: March 06, 2026
Re: Riccardo Bertolo, Antonio Luigi Pastore, Paolo Verze, et al. Real-World Burden and Management of Late Genitourinary Toxicity After Prostate Radiotherapy: Insights from IRRADIaTE, the Italian Registry of Radiotherapy-Associated Disorders and Urological Treatment & Evaluation. Eur Urol Oncol. 2026;9:408-416. https://doi.org/10.1016/j.euo.2026.01.005.
Journal: European urology oncology
Published: February 04, 2026
Last Updated: 09/26/2026